# Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

> **NCT01399008** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 100 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Arhalofenate
- **DRUG:** Allopurinol
- **DRUG:** Colchicine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01399008
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01399008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01399008, "Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01399008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*